Teva Pharma (TEVA) and Medincell Report Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Teva Pharma (TEVA) and Medincell Report Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

May 8, 2024 6:30 AM EDT

The study met its primary endpoint achieving clinically meaningful and statistically significant reductions across all TEV-749 dose groups versus placebo in the Positive and Negative Syndrome Scale (PANSS) total score, a widely used assessment tool for schizophrenia symptom severity TEV-749 was well tolerated, with no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date: additional safety data is being collected as part of the long-term... More